01 Growing Demand for Glutamine in Sports Nutrition and Functional Products The glutamine market is witnessing increasing demand from sports nutrition and wellness products as consumers become more focused on fitness, recovery, and active lifestyles. Glutamine is being incorporated into powders, capsules, and functional formulations targeting athletes and health-conscious consumers. The broader sports nutrition market is also expanding as fitness participation and awareness of nutritional supplementation increase. For instance, in 2025, amino acid supplements continued gaining attention among active and health-conscious consumers, with glutamine being promoted for recovery and immune-support applications, although evidence for direct muscle-growth benefits remains limited.
02 Rising Innovation in Powder-Based and Convenient Glutamine Formulations Manufacturers are increasingly focusing on convenient glutamine formats, particularly powders, capsules, and other easy-to-use formulations. Online retail is also becoming an important channel as consumers increasingly research and purchase nutritional supplements through digital platforms. This shift is encouraging brands to improve product convenience, formulation quality, and accessibility across sports nutrition and wellness categories. For instance, in 2025, glutamine market research identified powder formulations and dietary supplements as important areas of product development, while online channels continued expanding access to amino-acid-based nutritional products.
March 2026 CJ CheilJedang announced the expansion of its specialty amino acid fermentation platform, increasing manufacturing capabilities for high-value amino acids used in nutrition, pharmaceuticals, and cell culture applications, including L-glutamine.
January 2026 Evonik expanded its Health Care business by increasing production capacity for cell culture ingredients and pharmaceutical excipients, including amino acid products such as L-glutamine, to meet growing demand from biologics manufacturers.
October 2025 Kyowa Hakko Bio Co., Ltd. expanded its CentoHA™ cell culture media ingredient portfolio, increasing production and supply capabilities for pharmaceutical amino acids, including L-glutamine, to support biopharmaceutical manufacturing.
June 2025 Ajinomoto Co., Inc. invested in Somite Therapeutics to accelerate AI-driven cell therapy technologies. The collaboration strengthens Ajinomoto's cell culture media business, where pharmaceutical-grade L-glutamine is a key ingredient for biomanufacturing.